Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials

Background: We aim to understand whether all patients with hormonal receptor (HR)-positive (+)/human epidermal growth factor receptor-2 (HER2)-negative (−) metastatic breast cancer (MBC) should receive cyclin D-dependent kinase (CDK) 4/6 inhibitor-based therapy as a first-line approach. Methods: A n...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Valentina, Berchialla, Paola, Giannarelli, Diana, Nisticò, Cecilia, Ferretti, Gianluigi, Gasparro, Simona, Russillo, Michelangelo, Catania, Giovanna, Vigna, Leonardo, Mancusi, Rossella Letizia, Bria, Emilio, Montemurro, Filippo, Cognetti, Francesco, Fabi, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896062/
https://www.ncbi.nlm.nih.gov/pubmed/31717791
http://dx.doi.org/10.3390/cancers11111661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896062/
https://www.ncbi.nlm.nih.gov/pubmed/31717791
http://dx.doi.org/10.3390/cancers11111661

Ejemplares similares